Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Arizona
View More
Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum
View More
A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs
View More
Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes
October 26, 2025
Register Now!
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa
View More
Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York
View More
Experience With Subcutaneous PD-L1 Inhibitor
October 14th 2025Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting operational challenges, including creating multiple electronic medical record (EMR) order sets, standardizing injection times and volumes across products, and addressing nursing workflow considerations during the 2- to 10-minute injection periods.
Experience With SubQ Nivolumab in Clinical Practice
October 7th 2025Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how pharmacokinetic equivalency across varied patient weights supports flat dosing, how immune-mediated adverse events remain unpredictable and not dose dependent, and how patients appreciate the mild, transient injection site reactions.
Equivalency of SubQ vs IV Nivolumab and Data From CheckMate-67T Breakdown
October 7th 2025Panelists discuss how the CheckMate-67T trial established noninferiority of subcutaneous nivolumab to intravenous (IV) nivolumab through pharmacokinetic end points, comparable efficacy (24% vs 18% overall response rate [ORR]), similar safety profiles with mostly mild injection site reactions, and FDA approval across all monotherapy indications.
Drivers for SubQ Interest in Oncology Practices and Clinic Workflow Changes
September 30th 2025Panelists discuss how subcutaneous checkpoint inhibitors offer benefits through reduced wait times, potential for injection rooms or examination room administration, streamlined pharmacy workflows, improved patient quality of life by making them feel less like “cancer patients,” and opportunities for home-based care delivery in underserved areas.
Challenges in IV Administration of Immune Checkpoint Inhibitors and Interest in SubQ
September 30th 2025Panelists discuss how intravenous (IV) administration of immune checkpoint inhibitors creates challenges, including infusion chair bottlenecks, lengthy multistep clinic visits, difficult venous access over time, and significant time burdens for both patients and health care systems.